Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 93 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Valvular Diseases Clear all

Conditions: Atrial Fibrillation, Cardiovascular Diseases, Arrhythmia, Valvular Disease
Interventions: Risk-Based Assessment for Cardiac Dysfunction; Device
Lead sponsor: Northwestern University; Other
Eligibility: 40 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cancer, Deep-vein Thrombosis of the Lower and Upper Extremities, Pulmonary Embolism, Non-valvular Atrial Fibrillation
Interventions: Retrospective Chart Review; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Dementia, Cognition Disorders, Cerebral Ischemic Events
Interventions: Dabigatran Etexilate, Warfarin; Drug
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 65 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Coronary Artery Disease, Valvular Heart Disease, Aorta Disease, Heart Failure
Interventions: Sugammadex administration; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Pulmonary Hypertension, Valvular Heart Disease, Congenital Heart Disease, Congestive Heart Failure, Pulmonary Embolism, Acute Coronary Syndrome
Interventions: Measuring Right Ventricular Size and Function; Diagnostic Test
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Aortic Valve Stenosis
Interventions: atorvastatin (Lipitor); Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Atrial Fibrillation, Obesity, Anticoagulants
Interventions: Apixaban; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 107,383 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Atrial Fibrillation
Interventions: Edoxaban, Warfarin; Drug
Lead sponsor: Electrophysiology Research Foundation; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Warren Township, New Jersey

Conditions: Heart Diseases, ASD - Atrial Septal Defect, VSD - Muscular Ventricular Septal Defect, PFO - Patent Foramen Ovale, PIVSD - Post Infarct Muscular Ventricular Septal Defect, Valvular Heart Disease
Interventions: Amplatzer™ Occlusion Devices, Epic™ Surgical Tissue Heart Valve devices; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: Not listed
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2039
U.S. locations: 13
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 9 more

Conditions: Severe Aortic Stenosis
Interventions: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Device
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: Not listed
Enrollment: 2,777 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 45
States / cities: Phoenix, Arizona • Los Angeles, California • Mountain View, California + 35 more

Conditions: Tricuspid Regurgitation, Tricuspid Valve Disease, Tricuspid Valvular Disorders
Interventions: VDyne Transcatheter Tricuspid Valve Replacement System; Device
Lead sponsor: VDyne, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 10
States / cities: Los Angeles, California • Detriot, Michigan • Minneapolis, Minnesota + 7 more

Conditions: Ischemic Mitral Regurgitation
Interventions: Ranolazine (Active drug), Placebo; Drug
Lead sponsor: University Cardiology; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation, Hypertension, Pyelonephritis, Acute Renal Failure, Renal Failure, Viral Hepatitis, Alcoholic Hepatitis, Steatohepatitis, Cirrhosis, Asthma, COPD, Bronchitis, Emphysema, Pneumonia, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, Diverticulitis, Peptic Ulcer Disease, Irritable Bowel Syndrome, Cholecystitis, Pancreatitis, Malabsorption Disorders, Celiac Sprue, Diabetes
Interventions: Not listed
Lead sponsor: Epic Research & Diagnostics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 353 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Coronary Artery Diseases, Valvular Heart Diseases
Interventions: Reiki/manual therapy; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 272 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Atrial Fibrillation
Interventions: Rivaroxaban (Xarelto, BAY59-7939); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 12,507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Coronary Artery Disease, Valvular Diseases, Vascular Diseases
Interventions: Not listed
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement, Conduction Defect, Heart Failure, Valvular Heart Disease, Ischemic Heart Disease, Cardiotoxicity, Myocardial Infarction, Dilated Cardiomyopathy, HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Syncope, Remodeling, Cardiac
Interventions: 15-minutes of sitting during COR ECG Acquistion; Device
Lead sponsor: Peerbridge Health, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Orange, California • Pasadena, California • Detroit, Michigan + 5 more

Conditions: Moderate Aortic Valve Stenosis
Interventions: Ataciguat, Placebo; Drug
Lead sponsor: Kardigan, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 1,276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 70
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 61 more

Conditions: Tricuspid Regurgitation
Interventions: Transcatheter Tricuspid Valve Replacement; Device
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 9
States / cities: Phoenix, Arizona • Wichita, Kansas • Hackensack, New Jersey + 5 more

Conditions: Atrial Fibrillation
Interventions: Pradaxa, dabigatran etexilate; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 26
States / cities: Hot Springs, Arkansas • Fremont, California • Moreno Valley, California + 21 more

Conditions: Aortic Stenosis
Interventions: Not listed
Lead sponsor: Lahey Clinic; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Burlington, Massachusetts

Conditions: Atrial Fibrillation
Interventions: Patient Decision Support Tool; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Bradycardia, Tachycardia, Atrial Fibrillation, Valvular Heart Disease
Interventions: continue warfarin through the procedure, Hold warfarin, Warfarin held with heparin transition.; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Baltimore, Maryland • Columbia, Maryland

Conditions: Atrial Fibrillation, Heart Failure
Interventions: Non-Interventional; Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 65 Years and older
Enrollment: 60,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Search by objective public record fields.

NOrthwestern Tempus AI-enaBLed Electrocardiography (NOTABLE) Trial

Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center

Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation

Sugammadex Titration in Cardiac Surgery Patients

Evaluating Right Ventricular (RV) Size and Function Using the Upper Valley RV Algorithm and Novel Imaging Modalities

The Effect of Lipitor on Aortic Stenosis

Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare

EdoxabaN or Warfarin Therapy In Device Procedures in Patients With Non-Valvular Atrial Fibrillation

Abbott Structural Heart Device Registry

Safety and Efficacy Continued Access Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement

Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation ( VISTA-US)

Effect of Ranolazine on Valvular Disease in Patients With Pacemakers

Prognostic Indicators as Provided by the EPIC ClearView

Clinical and Hospital Stay Effects of Reiki and Manual Therapy After Open Heart Surgery

Real-world Dosing Patterns of Rivaroxaban in the United States

Factors Affect Outcomes in Cardiovascular Surgery

AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor

Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study

Global Multicenter Registry on Transcatheter TRIcuspid Valve RePLACEment

Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function

Ventricular Remodeling In Patients With Aortic Stenosis Assessed Echocardiography

Shared Decision Making to Address Racial Disparities in Oral Anticoagulation in NVAF

Randomized Study of the Use of Warfarin During Pacemaker or ICD Implantation in Patients Requiring Long Term Anticoagulation

Effectiveness of Oral Anticoagulants in Elderly Patients With Non-Valvular Atrial Fibrillation and Heart Failure